戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ment of therapies to prevent smoking-related lung disorders).
2 in-2 deficiency is the clear culprit in this lung disorder.
3 ransbronchial biopsy to diagnose parenchymal lung disorders.
4 cholestatic liver diseases, and inflammatory lung disorders.
5 ructive pulmonary disease and other advanced lung disorders.
6 icrobial communities associated with chronic lung disorders.
7 diseases, with a focus on cardiovascular and lung disorders.
8 tial therapeutic avenues in the treatment of lung disorders.
9 (chILD) comprises a spectrum of rare diffuse lung disorders.
10 irway surfaces of patients with inflammatory lung disorders.
11 athogenesis of a number of acute and chronic lung disorders.
12 he expression of MME by Mphi in inflammatory lung disorders.
13 ory distress syndrome and other inflammatory lung disorders.
14 iseases (ILDs) comprise over 200 parenchymal lung disorders.
15 ing a potential role of SPs in Th-associated lung disorders.
16  to viral infections associated with chronic lung disorders accompanied by chronic goblet cell metapl
17 thologically diagnosed interstitial neonatal lung disorders: acinar dysplasia (n = 14), congenital al
18 arge-scale utilization and human evidence of lung disorders and carcinogenicity, it is imperative to
19 ical tools in patients with asthma and other lung disorders and to explore some of the new developmen
20 ses including neurodevelopmental, renal, and lung disorders, and cancer.
21                                              Lung disorders are especially advantaged, as the pulmona
22 ion and five of six patients without primary lung disorder but in only one of six with parenchymal lu
23 re associated with several acute and chronic lung disorders, but their implications in the molecular
24 ill include the cure of the major hereditary lung disorders by gene therapy, new treatment for asthma
25 c beryllium disease (CBD) is a granulomatous lung disorder caused by a hypersensitivity to beryllium
26 hronic beryllium disease (CBD) is a fibrotic lung disorder caused by beryllium (Be) exposure and is c
27               Chronic beryllium disease is a lung disorder caused by beryllium exposure in the workpl
28 c bronchopulmonary aspergillosis (ABPA) is a lung disorder caused by immune-mediated reactions mounte
29  disease (CBD), a debilitating granulomatous lung disorder characterized by accumulations of berylliu
30                    Asthma is a heterogeneous lung disorder characterized by airway inflammation and a
31 n chronic beryllium disease, a granulomatous lung disorder characterized by CD4(+) T cell alveolitis
32 c beryllium disease (CBD) is an occupational lung disorder characterized by granulomatous inflammatio
33 ic obstructive pulmonary disease (COPD) is a lung disorder characterized by progressive airflow obstr
34                                These chronic lung disorders (CLD) may coexist in the same patient as
35 modality for diagnosing and managing chronic lung disorders, encompassing conditions such as pneumoni
36  airway obstruction) and six without primary lung disorder (Group 2).
37                          Mutation-associated lung disorders have been well studied, but less is known
38            These data establish that certain lung disorders, if of cell-autonomous hematopoietic orig
39 lmonary alveolar proteinosis (PAP) is a rare lung disorder in which surfactant-derived lipoproteins a
40 0 patients under neuromuscular blockade with lung disorders including moderately severe restrictive (
41 ed as a treatment option for several chronic lung disorders including pulmonary fibrosis.
42 ngoing clinical research networks with other lung disorders, including acute respiratory distress syn
43 ung induces features of chronic inflammatory lung disorders, including an eosinophil-rich inflammator
44 scription factors are upregulated in chronic lung disorders, including asthma.
45 ogenesis is associated with severe pediatric lung disorders, including bronchopulmonary dysplasia (BP
46 ary fibrosis is a common feature of numerous lung disorders, including interstitial lung diseases, as
47 monary alveolar proteinosis (aPAP) is a rare lung disorder involving production of autoantibodies aga
48  remodeling of the ECM occurs during several lung disorders, it is not known how fiber structure and
49 Despite the importance of fibroproliferative lung disorders, no safe and effective therapies exist fo
50               Sarcoidosis is a granulomatous lung disorder of unknown cause.
51 iopathic pulmonary fibrosis is a devastating lung disorder of unknown etiology.
52 nary fibrosis (IPF) is a chronic progressive lung disorder of unknown etiology.
53 is for combination therapies in interstitial lung disorders other than idiopathic pulmonary fibrosis.
54 to IPF and also occur in other aging-related lung disorders, primarily chronic obstructive pulmonary
55 e effects of IL-36 cytokines in inflammatory lung disorders remains poorly understood.
56 -CSF, interleukin (IL)-3, and IL-5 exhibit a lung disorder similar to human pulmonary alveolar protei
57 also shows potential therapeutic benefits in lung disorders such as acute lung injury, pulmonary fibr
58 uld revolutionise treatment of patients with lung disorders such as cancer, acute respiratory distres
59 metalloelastase (MME) has been implicated in lung disorders such as emphysema and pulmonary fibrosis,
60  for extracellular vesicles (EVs) in driving lung disorders, such as chronic obstructive pulmonary di
61              Pulmonary fibrosis is a serious lung disorder that can lead to respiratory failure.
62  disease (LCDD) presenting as diffuse cystic lung disorder that differs from the usual systemic form
63  (ARDS) is a relatively common, inflammatory lung disorder that is associated with major morbidity an
64 ic beryllium (Be) disease is a granulomatous lung disorder that results from Be exposure in a genetic
65 g diseases encompass a wide range of diffuse lung disorders that are often complicated by the develop
66 represent two classes of chronic obstructive lung disorders that may share some similar immunologic m
67 ess syndrome (ARDS) is a severe inflammatory lung disorder triggered by pneumonia, sepsis, trauma, an
68 ts), disease progression (two patients), and lung disorder (two patients).
69  pathophysiologic processes of fiber-induced lung disorders was examined.
70 cal presentation in sepsis, COVID, and other lung disorders where vascular fluid leakage is a severe
71 onary fibrosis (IPF) is a morbid, refractory lung disorder with an unknown pathogenesis.
72 ic pulmonary fibrosis (IPF) is a devastating lung disorder with increasing incidence.
73 pulmonary fibrosis (IPF) is a fatal fibrotic lung disorder with no effective medical treatments avail